Table 2

Histology and p53 immunohistochemistry in biopsy series of cases and controls

 ControlsCasesRR (95% CI)RR* (95% CI)
n=1300n=132
Histology
 ND1011 (78%)74 (56%)ReferenceReference
 LGD289 (22%)58 (44%)4.2 (2.4 to 7.3)4.0 (2.3 to 7.0)
P53 immunohistochemistry
 Normal p53 expression1115 (86%)67 (51%)ReferenceReference
 Aberrant p53 expression185 (14%)65 (49%)6.2 (3.6 to 10.9)6.4 (3.6 to 11.3)
 P53 overexpression169 (13%)58 (44%)5.5 (3.1 to 10.0)5.6 (3.1 to 10.3)
 Loss of p53 expression16 (1%)7 (5%)13.4 (5.1 to 35.3)14.0 (5.3 to 37.2)
Histology and p53 immunohistochemistry
 ND and normal p53 expression918 (71%)50 (38%)ReferenceReference
 LGD and normal p53 expression197 (15%)17 (13%)2.4 (0.9 to 6.0)2.2 (0.8 to 5.5)
 ND and aberrant p53 expression93 (7%)24 (18%)4.5 (2.0 to 10.0)4.3 (1.9 to 9.8)
 LGD and aberrant p53 expression92 (7%)41 (31%)11.2 (5.7 to 22.0)12.2 (6.1 to 24.5)
  • *Adjusted for age, gender, Barrett length and oesophagitis.

  • The highest degree of abnormality was reported for each endoscopy after examining all biopsies.

  • Loglinear regression models were used to calculate relative risks (RRs) and CIs for neoplastic progression.

  • LGD, low-grade dysplasia; ND, no dysplasia.